focus -WSS

focus

author：knowledge 2025-10-02 14:56:42 Page View：37454

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare Advantage proposed rates disappoint insurers
Next article： As demand for Covid shots wanes, Moderna seeks its next success

Wikipedia

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

The best solution to the drug shortages problem

AdobeDrugshortagesintheUnitedStatesareatarecordhigh.Atleast14essentialgenericcancerdrugsarecurrently

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

1:03FormerPresidentDonaldTrumpspeaksbeforeheboardshisplaneatRonaldReaganWashingtonNationalAirport,Au